| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0099 | 0.8 |
| mRNA | CEP-701 | GDSC1000 | pan-cancer | AAC | 0.0099 | 0.8 |
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | -0.016 | 0.8 |
| mRNA | MS-275 | GDSC1000 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | HG-5-88-01 | GDSC1000 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | -0.0093 | 0.8 |
| mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | 0.0093 | 0.8 |
| mRNA | MLN2480 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | 0.049 | 0.8 |